Veliparib plus temozolomide did not significantly extend overall survival in patients with newly diagnosed, ...

Dr. Sattva S. Neelapu discusses the intricacies of CAR T-cell therapy treatment and care for patients with hematologic ...

The objective response rate was 78.6% in the overall cohort, 76.9% in patients with a PD-L1 combined positive score (CPS) below 1, 68.8% in patients with a PD-L1 CPS of 1-9, and 100% in patients with ...

The FDA approved inavolisib for triplet combination use for treatment of PIK3CA-mutated locally advanced or metastatic ...

Johnson & Johnson (J&J) has reported positive topline outcomes from the Phase III MARIPOSA trial of RYBREVANT ...

The phase 4 PADMA study showed meaningful improvements in TFF and PFS in patients with high-risk HR-positive/HER2-negative metastatic breast cancer.

Now, China-based CARsgen has shared pivotal results from the latter portion of a phase 1/2 study evaluating the therapy for ...

Mark A. Lewis, MD, discussed the promise of the ESOPEC and TRANSMET trials and the need for their further investigation.

Researchers sought to determine whether patients with PMBCL may be able to forgo irradiation therapy during consolidation.

In the first long-term ... Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free survival in patients with endocrine therapy ...

A paper published in the Journal of Clinical Oncology, titled "Comparative Analysis of Intracranial Response Assessment ...

T-cell therapy yielded encouraging response rates and safety findings among patients with relapsed or refractory chronic ...